ArticleCancers2020

Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3.

Anselm Morell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.